AZD4547, a new-type specific FGFR inhibitor, targets for FGFR1/2/3 (IC50: 0.2/2.5/1.8 nM in cell-free assays).

FGFR4-IN-14 (Compound 27i) is a selective FGFR4 inhibitor with an IC50 of 2.4 nM, showing potent inhibition of cell proliferation in the V550L and N535K mutant strains. Specifically, it registers IC50 values of 21 nM against Huh7 cells, 2.5 nM against BaF3/ETV6-FGFR4-V550L cells, and 171 nM against BaF3/ETV6-FGFR4-N535K cells. Demonstrating significant antitumor efficacy in the Huh7 xenograft model, FGFR4-IN-14 is utilized in the research of hepatocellular carcinoma (HCC) [1].

Resigratinib (KIN-3248) is a FGFR tyrosine kinase inhibitor exhibiting antineoplastic activity [1].

Heparan Sulfate, a complex and linear polysaccharide, forms a component of glycoproteins called heparan sulfate proteoglycans, abundantly expressed on the cell surface and within the extracellular matrix.

Masitinib (AB1010) is a tyrosine-kinase inhibitor used in the treatment of mast cell tumors in animals, specifically dogs. Since its introduction in November 2008 it has been distributed under the commercial name Masivet. It has been available in Europe since the second part of 2009. In the USA it is distributed under the name Kinavet and has been available for veterinaries since 2011.